stockrow
Saturday 7 November 2026
Export ODTX’s income statement to Excel — free account
Odyssey Therapeutics, Inc.
ODTX Healthcare Biotechnology
19.13
0.25
+1.32%
Follow ODTX
Alert me
| Sep '26 | Jun '26 | Mar '26 | Dec '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
— | — | — | — |
+3 more quarters Free account |
EV/Sales |
— | — | — | — | |
EV/FCF |
— | — | — | — | |
Quick Ratio |
12.49 | 10.98 | 7.91 | 6.85 | |
Current Ratio |
12.94 | 11.36 | 8.33 | 7.20 | |
Net Debt/EBITDA |
5.86 | 5.71 | 4.55 | 0.00 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
— | 0.00 | — | — | |
Operating CF/Net income |
0.78 | 0.65 | 1.07 | — | |
Capex/Depreciation |
(0.48) | 0.09 | (0.13) | — | |
Interest Coverage |
(4,722.33) | (2,773.50) | (3,978.00) | — | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | — | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | — | |
Intangible Assets out of Total Assets |
0.03 | 0.03 | 0.06 | 0.05 | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | — | |
Free Cash Flow Yield |
— | — | — | — | |
Revenue per Share |
0.00 | 0.00 | 0.00 | — | |
Operating CF per Share |
(0.87) | (1.14) | (7.26) | — | |
Capex per Share |
(0.01) | 0.00 | (0.03) | — | |
Free Cash Flow per Share |
(0.88) | (1.14) | (7.28) | — | |
Cash per Share |
6.79 | 10.26 | 31.07 | 0.00 | |
Shareholders Equity per Share |
7.83 | 13.91 | 31.80 | 0.00 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | — | |
Book value per Share |
7.83 | 13.91 | 31.80 | 0.00 | |
Free Cash Flow |
(42.02) | (34.41) | (41.18) | — | |
Working Capital |
311.70 | 293.17 | 162.89 | 164.18 | |
Capital Expenditures |
(0.48) | 0.10 | (0.15) | — | |
Net Current Asset Value |
275.47 | 258.83 | 135.90 | 136.15 | |
EV/EBIT |
— | — | — | — | |
Capex to Sales |
0.00 | 0.00 | 0.00 | — | |
| Other line items | |||||
Average Assets |
— | 241.93 | — | — |
Columns are period end dates · fundamentals updated 6 Nov 2026